(Total Views: 762)
Posted On: 05/16/2024 2:51:37 PM
Post# of 154130
“The prospective clinical trials, in order of priority, are: (i) a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer”
CRC has often been mentioned by Cytodyn as a clinical target but this just punched up to top priority. It makes you curious why. My bet is that there may be potential partner interest. I will note here Merck’s drug Keytruda (pembrolizumab) is a key player with FDA approval for CRC and it is well known they hit the patent cliff in 4 years. Combo therapy could have a significant clinical impact if Leronlimab proves effective for the microsatellite-stable subpopulation.
“In recent years, immunotherapy strategies based on immune checkpoint inhibitors have yielded good efficacy in colorectal cancer (CRC)especially in colorectal cancer with microsatellite instability-high. However, microsatellite-stable (MSS) CRCs account for about 85% of CRCs and are resistant to immunotherapy. Previous studies have shown that compared with MSS CRC, high microsatellite instability CRC possesses a higher frequency of mutations and can generate more neoantigens. Therefore, improving the sensitivity of immunotherapy to MSS CRC is a hot topic which is crucial for the treatment of MSS CRC. ”
https://academic.oup.com/pmj/advance-article-...=fulltext#
CRC has often been mentioned by Cytodyn as a clinical target but this just punched up to top priority. It makes you curious why. My bet is that there may be potential partner interest. I will note here Merck’s drug Keytruda (pembrolizumab) is a key player with FDA approval for CRC and it is well known they hit the patent cliff in 4 years. Combo therapy could have a significant clinical impact if Leronlimab proves effective for the microsatellite-stable subpopulation.
“In recent years, immunotherapy strategies based on immune checkpoint inhibitors have yielded good efficacy in colorectal cancer (CRC)especially in colorectal cancer with microsatellite instability-high. However, microsatellite-stable (MSS) CRCs account for about 85% of CRCs and are resistant to immunotherapy. Previous studies have shown that compared with MSS CRC, high microsatellite instability CRC possesses a higher frequency of mutations and can generate more neoantigens. Therefore, improving the sensitivity of immunotherapy to MSS CRC is a hot topic which is crucial for the treatment of MSS CRC. ”
https://academic.oup.com/pmj/advance-article-...=fulltext#
(15)
(0)
